Cresco LabsFRA:6CQ +6.77%66 EBITDA Margin % is 17.61% as of Mar. 2026. GuruFocus rates FRA:6CQ with a GF Score™ of 66/100 and a GF Value™ of €0.88 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 955 Drug Manufacturers companies, Cresco Labs ranks worse than 72.36% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cresco Labs's EBITDA for the
three
months ended in Mar. 2026 was €23.0 Mil. Cresco Labs's Revenue for the
three
months ended in Mar. 2026 was €130.9 Mil. Therefore, Cresco Labs's EBITDA margin for the quarter that ended in Mar. 2026 was 17.61%.
Cresco Labs (FRA:6CQ) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cresco Labs EBITDA Margin % Related Terms
Cresco Labs EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Cresco Labs's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cresco Labs's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cresco Labs EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cresco Labs's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cresco Labs's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cresco Labs (FRA:6CQ) has a EBITDA Margin % of 17.61% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cresco Labs and its competitors. According to the industry distribution chart, Cresco Labs ranks #691 out of 955 companies in the Drug Manufacturers industry, placing it in the top 72.4%.
Is Cresco Labs' EBITDA Margin % too high?
Cresco Labs' current EBITDA Margin % is 17.61%. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Cresco Labs' value of 17.61% is 41.6% above this industry median. Based on the distribution chart, Cresco Labs ranks #691 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cresco Labs has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cresco Labs' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cresco Labs ranks #691 out of 955 companies for EBITDA Margin %. This places Cresco Labs in the lower half of its industry. The industry median EBITDA Margin % is 12.44. Cresco Labs' value of 17.61% is 41.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cresco Labs's current EBITDA Margin % of 17.61% is 41.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cresco Labs and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cresco Labs's current EBITDA Margin % is 17.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cresco Labs stock overvalued right now?
Based on GuruFocus' analysis, Cresco Labs (FRA:6CQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.88, compared to a current price of €0.69 — trading 21.1% below its estimated fair value. The current EBITDA Margin % is 17.61% and 41.6% above the Drug Manufacturers industry median of 12.44. Cresco Labs' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cresco Labs (FRA:6CQ), the current EBITDA Margin % is 17.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cresco Labs (FRA:6CQ) Overvalued in 2026?
Based on GuruFocus' analysis, Cresco Labs stock appears to be undervalued.
The current stock price of €0.69 is trading 21.1% below its estimated GF Value™ of €0.88.
GuruFocus considers Cresco Labs to be Modestly Undervalued.
Key valuation signals for FRA:6CQ:
EBITDA Margin %: 17.61%
GF Value™: €0.88 vs. price of €0.69 (21.1% below fair value)
Industry Position: 41.6% above the Drug Manufacturers median (#691 of 955)
No single metric tells the full story. See the FRA:6CQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cresco Labs Inc is a vertically-integrated multi-state cannabis operator in the United States licensed to cultivate, manufacture, and sell retail and medical cannabis products through Sunnyside, Cresco Lab's national dispensary brand, and others. The company operates in one segment: the cultivation, manufacturing, distribution, and sale of cannabis. The company's brand includes: Cresco, High Supply, FloraCal Farms, Good News, Wonder Wellness Co., Mindy's, and Remedi.
66GF Score
Get the complete analysis for FRA:6CQ
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6CQ has been successfully added to your 
